Status:
UNKNOWN
Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Monkey Pox
Monkey Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Since one month (first case confirmed the 05/06/2022), some cases of non-imported were reported by Portuguese and British authorities then in several Europeans countries, the US and the Canada. The 05...
Detailed Description
Indication for Post-Exposure vaccination (PEP) : PEP has demonstrated its interest in different situations, in particular rabies, tetanus or hepatitis B, as recalled in the report "Guide for post-exp...
Eligibility Criteria
Inclusion
- \- PEP group : Be a contact at risk of exposure to the Monkeypox virus as recommended by the HAS within at less 14 days and not vaccinated OR Be a contact at risk of exposure to the Monkeypox virus as recommended by the HAS within at less 14 days and who received the first injection of PEV less than 28 days ago
- \- PrEP group : Be identified as belonging to the groups most exposed to MPXV, as defined by HAS, but not be a contact person at risk and not have received an MVA vaccine
- \- Signature of informed consent
Exclusion
- Be under guardianship or curatorship
- No covered by social security
- Subject to a legal protection measure
- Have a contraindication to Monkeypox vaccination
- Have a known or suspected allergy to one of the components of the vaccine- Diagnosis of Monkeypox
Key Trial Info
Start Date :
July 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2024
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT05438953
Start Date
July 12 2022
End Date
October 1 2024
Last Update
October 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CIC Cochin-Pasteur
Paris, France